Annual report [Section 13 and 15(d), not S-K Item 405]

Note 9 - Accrued Liabilities

v3.25.1
Note 9 - Accrued Liabilities
12 Months Ended
Dec. 31, 2024
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

9.

Accrued Liabilities

 

Accrued liabilities consisted of the following (in thousands):

 

   

December 31, 2024

   

December 31, 2023

 

Clinical trial costs

  $ 2,277     $ 258  

Compensation

    1,060       766  

Research and development services

    888       632  

Professional services fees

    112       98  

Other

    10       23  

Total accrued liabilities

  $ 4,347     $ 1,777